[The results of clinical trials and the prospects of using the Soviet preparation of human recombinant interferon alpha-2 (reaferon) in medical practice].
The results of the clinical trials of human recombinant interferon alpha-2 (reaferon) make it possible to come to the conclusion that the preparation is well-tolerated and produces a pronounced therapeutic effect in a number of viral and oncological diseases. The Pharmacological Committee of the USSR has recommended reaferon for use in acute hepatitis B, hairy cell leukemia, renal cancer at stage IV, disseminated sclerosis, ocular herpes. The use of reaferon has been found to be promising in the treatment of papillomatosis of the larynx, Kaposi's sarcoma, mycosis fungoides, chronic myeloleukemia.
Kalinin
Iu T
IuT
Vorob'ev
A A
AA
Bumialis
V V
VV
Denisov
L A
LA
Parfenov
V V
VV
Klenova
A V
AV
Ianulaĭtis
A A
AA
Ershov
F I
FI
Marchenko
V I
VI
Malinovskaia
V V
VV
D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014586:USSR
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Rezul'taty klinicheskikh ispytaniĭ i perspektivy primeneniia v meditsinskoĭ praktike otechestvennogo rekombinantnogo preparata chelovecheskogo interferona al'fa-2 (reaferona).